Hemoglobin-based oxygen carriers: Current status and future directions

Transfusion

Volumn 49, Issue 11, 2009, Pages 2495-2515

  Silverman, Toby A ^a   Weiskopf, Richard B ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLASE; ARTIFICIAL BLOOD; BLOOD SUBSTITUTE; DIASPIRIN CROSSLINKED HEMOGLOBIN; HEMEASSIST; HEMOGLOBIN; HEMOGLOBIN DERIVATIVE; HEMOSPAN; NITRIC OXIDE; POLYMERIZED HEMOGLOBIN; RECOMBINANT HEMOGLOBIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ARTERY THROMBOSIS; ASPIRATION PNEUMONIA; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD SUBSTITUTION; BRAIN ISCHEMIA; CARDIOPULMONARY ARREST; CENTRAL VENOUS PRESSURE; CEREBROVASCULAR ACCIDENT; CHEST TIGHTNESS; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CYANOSIS; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FATALITY; DUODENAL ULCER BLEEDING; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ERUCTATION; ESOPHAGUS SPASM; GASTRIC ULCER BLEEDING; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART ARRHYTHMIA; HEART INDEX; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART VENTRICLE FIBRILLATION; HEMIPARESIS; HEMIPLEGIA; HEMORRHAGIC SHOCK; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOVOLEMIA; HYPOXEMIA; HYPOXIA; ILEUS; LIVER FUNCTION TEST; LOWER ABDOMINAL PAIN; LUNG EDEMA; LUNG EMBOLISM; MALIGNANT HYPERTENSION; MEDICAL RESEARCH; MULTIPLE ORGAN FAILURE; NONHUMAN; OUTCOME ASSESSMENT; OXYGEN TRANSPORT; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PETECHIA; PNEUMONIA; POSTGRADUATE EDUCATION; PULMONARY HYPERTENSION; PURPURA; RECTUM HEMORRHAGE; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RETCHING; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THORAX PAIN; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VAGINA BLEEDING; VOMITING;

CONGRESSES AS TOPIC; HEMOGLOBINS; NATIONAL INSTITUTES OF HEALTH (U.S.); OXYGEN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70449127973     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02356.x     Document Type: Conference Paper

References (89)

1. U.S. Food and Drug Adminstration. April 29, 2008 Transcripts: Safety of Hemoglobin-Based Oxygen Carriers (HBOCs). Updated May 19, 2009 2008 cited 2009 Jul 6]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/ NewsEvents/WorkshopsMeetingsConferences/ucm092010.htm.
2. U.S. Food and Drug Adminstration. April 30, 2008 Transcripts: Safety of Hemoglobin-Based Oxygen Carriers (HBOCs). Updated May 19, 2009 2008 cited 2009 Jul 6]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/ NewsEvents/WorkshopsMeetingsConferences/ucm106954.htm.
3. Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996 380 : 221 6. (Pubitemid 26090643)
4. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO 3rd, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003 9 : 1498 505.
5. Winslow RM. Targeted O2 delivery by low-p50 hemoglobin: a new basis for hemoglobin-based oxygen carriers. Artif Cells Blood Substit Immobil Biotechnol 2005 33 : 1 12.
6. Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol 2003 285 : H1411 9.
7. Cabrales P, Tsai AG, Winslow RM, Intaglietta M. Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin. Am J Physiol Heart Circ Physiol 2005 289 : H2392 400.
8. Hare GM, Hum KM, Kim SY, Barr A, Baker AJ, Mazer CD. Increased cerebral tissue oxygen tension after extensive hemodilution with a hemoglobin-based oxygen carrier. Anesth Analg 2004 99 : 528 35.
9. Torres Filho IP, Spiess BD, Barbee RW, Ward KR, Oldenhof J, Pittman RN. Systemic responses to hemodilution after transfusion with stored blood and with a hemoglobin-based oxygen carrier. Anesth Analg 2005 100 : 912 20.
10. Hungerer S, Nolte D, Botzlar A, Messmer K. Effects of Diaspirin Crosslinked Hemoglobin (DCLHb) on microcirculation and local tissue pO2 of striated skin muscle following resuscitation from hemorrhagic shock. Artif Cells Blood Substit Immobil Biotechnol 2006 34 : 455 71.
11. Ding H, Triggle C. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag 2005 1 : 55 71.
12. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004 15 : 1983 92.
13. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharrón JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006 5 : 4.
14. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000 283 : 2701 11.
15. Vandegriff K, Young M, Keipert P, Winslow R. The safety profile of Hemospan®: a new oxygen therapeutic designed using maleimide poly(ethylene) glycol conjugation to human hemoglobin. Transfus Altern Transfus Med 2008 9 : 213 25.
16. Winslow RM. Red cell substitutes. Semin Hematol 2007 44 : 51 9.
17. Olofsson C, Ahl T, Johansson T, Larsson S, Nellgård P, Ponzer S, Fagrell B, Przybelski R, Keipert P, Winslow N, Winslow RM. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology 2006 105 : 1153 63.
18. Olofsson C, Nygards EB, Ponzer S, Fagrell B, Przybelski R, Keipert PE, Winslow N, Winslow RM. A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia. Transfus Med 2008 18 : 28 39.
19. Gould SA, Moore EE, Hoyt DB, Ness PM, Norris EJ, Carson JL, Hides GA, Freeman IH, DeWoskin R, Moss GS. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg 2002 195 : 445 52, discussion 52-5.
20. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002 42 : 812 8.
21. Moore EE, Cheng AM, Moore HB, Masuno T, Johnson JL. Hemoglobin-based oxygen carriers in trauma care: scientific rationale for the US multicenter prehospital trial. World J Surg 2006 30 : 1247 57.
22. Dunnett CW, Gent M. An alternative to the use of two-sided tests in clinical trials. Stat Med 1996 15 : 1729 38.
23. Jahr JS, Mackenzie C, Pearce LB, Pitman A, Greenburg AG. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008 64 : 1484 97.
24. Kerner T, Ahlers O, Veit S, Riou B, Saunders M, Pison U European DCLHb Trauma Study Group. DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study. Intensive Care Med 2003 29 : 378 85.
25. Sloan EP, Koenigsberg M, Brunett PH, Bynoe RP, Morris JA, Tinkoff G, Dalsey WC, Ochsner MG DCLHb Traumatic Hemorrhagic Shock Study Group. Post hoc mortality analysis of the efficacy trial of diaspirin cross-linked hemoglobin in the treatment of severe traumatic hemorrhagic shock. J Trauma 2002 52 : 887 95.
26. Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MN, Rodman G Jr. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999 282 : 1857 64.
27. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, Schreiber MA, Gonzalez EA, Pomper GJ, Perkins JG, Spinella PC, Williams KL, Park MS. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008 248 : 447 58.
28. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008 299 : 2304 12.
29. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008 73 : 538 46.
30. Viele MK, Weiskopf RB, Fisher D. Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. Anesthesiology 1997 86 : 848 58.
31. Solomon R, Segal A. Defining acute kidney injury: what is the most appropriate metric? Nat Clin Pract Nephrol 2008 4 : 208 15.
32. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, MacKinnon RW, Li L, Balakrishnan VS, Pereira BJ, Bonventre JV, Jaber BL. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007 18 : 904 12.
33. Ronco C. N-GAL: diagnosing AKI as soon as possible. Crit Care 2007 11 : 173.
34. Dong F, Hall CH, Golech SA, Philbin NB, Rice JP, Gurney J, Arnaud FG, Hammett M, Ma X, Flournoy WS, Hong J, Kaplan LJ, Pearce LB, Mcgwin G, Ahlers S, Mccarron R, Freilich D. Immune effects of resuscitation with HBOC-201, a hemoglobin-based oxygen carrier, in swine with moderately severe hemorrhagic shock from controlled hemorrhage. Shock 2006 25 : 50 5.
35. Burhop K, Gordon D, Estep T. Review of hemoglobin-induced myocardial lesions. Artif Cells Blood Substit Immobil Biotechnol 2004 32 : 353 74.
36. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007 110 : 2166 72.
37. Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, Stern KN, Koudstaal PJ. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke 1999 30 : 993 6.
38. Qu Y, Chen J, Benvenisti-Zarom L, Ma X, Regan RF. Effect of targeted deletion of the heme oxygenase-2 gene on hemoglobin toxicity in the striatum. J Cereb Blood Flow Metab 2005 25 : 1466 75.
39. Panter SS, Vandegriff KD, Yan PO, Regan RF. Assessment of hemoglobin-dependent neurotoxicity: alpha-alpha crosslinked hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 1994 22 : 399 413.
40. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005 293 : 1653 62.
41. Gladwin MT, Schechter AN, Kim-Shapiro DB, Patel RP, Hogg N, Shiva S, Cannon RO 3rd, Kelm M, Wink DA, Espey MG, Oldfield EH, Pluta RM, Freeman BA, Lancaster JR Jr, Feelisch M, Lundberg JO. The emerging biology of the nitrite anion. Nat Chem Biol 2005 1 : 308 14.
42. Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, Huang KT, Ho C, Hogg N, Schechter AN, Gladwin MT. Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest 2005 115 : 2099 107.
43. Olson JS, Maillett DH. Designing recombinant hemoglobin for use as a blood substitute. In : Winslow R, editor. Blood substitutes. London : Elsevier 2005. p. 354 74.
44. Graves PE, Henderson DP, Horstman MJ, Solomon BJ, Olson JS. Enhancing stability and expression of recombinant human hemoglobin in E. coli: progress in the development of a recombinant HBOC source. Biochim Biophys Acta 2008 1784 : 1471 9.
45. Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, Lemon DD. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 2004 36 : 685 97.
46. Dou Y, Maillett DH, Eich RF, Olson JS. Myoglobin as a model system for designing heme protein based blood substitutes. Biophys Chem 2002 98 : 127 48.
47. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olson JS, Lemon DD. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 1998 16 : 672 6.
48. Cabales P, Friedman J. Pegylated hemoglobins mechanisms to avoid vasoconstriction and maintain perfusion. Transfus Altern Transfus Med 2008 9 : 281 93.
49. Acharya S, Intaglietta M, Tsai A. Modulation of the PEH-Hb structure to increase the efficiency of plasma expansion and O2 carrying capacity. Transfus Altern Transfus Med 2007 9 : 254 64.
50. Fleming TR. Identifying and addressing safety signals in clinical trials. N Engl J Med 2008 359 : 1400 2.
51. Severinghaus JW. Oxyhemoglobin dissociation curve correction for temperature and pH variation in human blood. J Appl Physiol 1958 12 : 485 6.
52. Severinghaus JW. Blood gas calculator. J Appl Physiol 1966 21 : 1108 16.
53. Sullivan B, Riggs A. Data for constructing blood oxygen dissociation curves. In : Altman PL, Dittmer DS, editors. Respiration and circulation. Bethesda (MD) : Federation of American Societies for Experimental Biology 1971. p. 180 4.
54. Nelson D, Hai T, Srnak A, Ebeling A, Kunas G, Catarello J, Burhop K. Synthesis and properties of polymerized, diaspirin cross-linked hemoglobins. Biomater Artif Cells Immobilization Biotechnol 1992 20 : 253 8.
55. Privalle C, Talarico T, Keng T, DeAngelo J. Pyridoxalated hemoglobin polyoxyethylene: a nitric oxide scavenger with antioxidant activity for the treatment of nitric oxide-induced shock. Free Radic Biol Med 2000 28 : 1507 17.
56. Nelson DJ. DCLHb and rHb1.1. In : Winslow RM, editor. Blood substitutes. London : Academic Press, Elsevier Inc 2006. p. 399 414.
57. Vandegriff KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion 2003 43 : 509 16.
58. Kramer GC, Nascimento PJ, Vaid SU. Hemoglobin-based oxygen carriers as resuscitative solutions for trauma and combat casualty care. In : Winslow RM, editor. Blood substitutes. London : Academic Press, Elsevier Inc 2006. p. 139 51.
59. Talarico TL, Guise KJ, Stacey CJ. Chemical characterization of pyridoxalated hemoglobin polyoxyethylene conjugate. Biochim Biophys Acta 2000 1476 : 53 65.
60. Riess JG. Oxygen carriers ("blood substitutes") - raison d'être, chemistry, and some physiology. Chem Rev 2001 101 : 2797 920.
61. Wicks D, Wong LT, Sandhu R, Stewart RK, Biro GP. The intravascular persistence and methemoglobin formation of Hemolink (hemoglobin raffimer) in dogs. Artif Cells Blood Substit Immobil Biotechnol 2003 31 : 1 17.
62. Spahn D, Chassot PG. Clinical trials in cardiac surgery. In : Winslow RM, editor. Blood substitutes. London : Academic Press, Elsevier Inc 2006. p. 163 68.
63. Rentko VT, Pearce LB, Moon-Massat PF, Gawryl MS. HBOC-201 (hemoglobin glutamer-250 (Bovine), Hemopure®): clinical studies. In : Winslow RM, editor. Blood substitutes. London : Academic Press, Elsevier Inc 2006. p. 437 50.
64. Winslow RM. Hemoglobin modification. In : Winslow RM, editor. Blood substitutes. London : Academic Press, Elsevier Inc 2006. p. 341 53.
65. Swan SK, Halstenson CE, Collins AJ, Colburn WA, Blue J, Przybelski RJ. Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Am J Kidney Dis 1995 26 : 918 23.
66. Przybelski RJ, Daily EK, Kisicki JC, Mattia-Goldberg C, Bounds MJ, Colburn WA. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit Care Med 1996 24 : 1993 2000.
67. Bloomfield EL, Rady MY, Esfandiari S. A prospective trial of diaspirin cross-linked hemoglobin solution in patients after elective repair of abdominal aortic aneurysm. Mil Med 2004 169 : 546 50.
68. Schubert A, Przybelski RJ, Eidt JF, Lasky LC, Marks KE, Karafa M, Novick AC, O'Hara JF, Saunders ME, Blue JW, Tetzlaff JE, Mascha E the Perioperative Avoidance or Reduction of Transfusion Trial (PARTT) Study Group. Diaspirin-crosslinked hemoglobin reduces blood transfusion in noncardiac surgery: a multicenter, randomized, controlled, double-blinded trial. Anesth Analg 2003 97 : 323 32.
69. Ward CG, Sloan EP. Post hoc mortality analysis on the efficacy trial of diaspirin cross-linked hemoglobin in the treatment of severe traumatic hemorrhagic shock. J Trauma 2002 53 : 1031 author reply -2.
70. Lamy ML, Daily EK, Brichant JF, Larbuisson RP, Demeyere RH, Vandermeersch EA, Lehot JJ, Parsloe MR, Berridge JC, Sinclair CJ, Baron JF, Przybelski RJ. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology 2000 92 : 646 56.
71. Garrioch MA, McClure JH, Wildsmith JA. Haemodynamic effects of diaspirin crosslinked haemoglobin (DCLHb) given before abdominal aortic aneurysm surgery. Br J Anaesth 1999 83 : 702 7.
72. Saxena R, Wijnhoud AD, Man in 't Veld AJ, van den Meiracker AH, Boomsma F, Przybelski RJ, Koudstaal PJ. Effect of diaspirin cross-linked hemoglobin on endothelin-1 and blood pressure in acute ischemic stroke in man. J Hypertens 1998 16 : 1459 65.
73. Reah G, Bodenham AR, Mallick A, Daily EK, Przybelski RJ. Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. Crit Care Med 1997 25 : 1480 8.
74. Sprung J, Kindscher JD, Wahr JA, Levy JH, Monk TG, Moritz MW, O'Hara PJ. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth Analg 2002 94 : 799 808, table of contents.
75. LaMuraglia GM, O'Hara PJ, Baker WH, Naslund TC, Norris EJ, Li J, Vandermeersch E. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vasc Surg 2000 31 : 299 308.
76. Standl T, Burmeister MA, Horn EP, Wilhelm S, Knoefel WT, Schulte am Esch J. Bovine haemoglobin-based oxygen carrier for patients undergoing haemodilution before liver resection. Br J Anaesth 1998 80 : 189 94.
77. Kasper SM, Grune F, Walter M, Amr N, Erasmi H, Buzello W. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1998 87 : 284 91.
78. Kasper SM, Walter M, Grune F, Bischoff A, Erasmi H, Buzello W. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1996 83 : 921 7.
79. Levy JH. The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss. Expert Opin Biol Ther 2003 3 : 509 17.
80. Levy JH, Goodnough LT, Greilich PE, Parr GV, Stewart RW, Gratz I, Wahr J, Williams J, Comunale ME, Doblar D, Silvay G, Cohen M, Jahr JS, Vlahakes GJ. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg 2002 124 : 35 42.
81. Serruys P, Vranckx P, Slagboom T, Regar E, Meliga E, De Winter RJ, Heyndrickx G, Schuler G, Van Remortel EA, Dube GP, Symons J. Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD. EuroIntervention 2008 3 : 600 9.
82. Greenburg AG, Kim HW. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery. J Am Coll Surg 2004 198 : 373 83, discussion 84-5.
83. Hill SE, Gottschalk LI, Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2002 16 : 695 702.
84. Carmichael FJ, Ali AC, Campbell JA, Langlois SF, Biro GP, Willan AR, Pierce CH, Greenburg AG. A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit Care Med 2000 28 : 2283 92.
85. Johnson JL, Moore EE, Offner PJ, Haenel JB, Hides GA, Tamura DY. Resuscitation of the injured patient with polymerized stroma-free hemoglobin does not produce systemic or pulmonary hypertension. Am J Surg 1998 176 : 612 7.
86. Gould SA, Moore EE, Moore FA, Haenel JB, Burch JM, Sehgal H, Sehgal L, DeWoskin R, Moss GS. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J Trauma 1997 43 : 325 31, discussion 31-2.
87. Gould SA, Moore EE, Hoyt DB, Burch JM, Haenel JB, Garcia J, DeWoskin R, Moss GS. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998 187 : 113 20, discussion 20-2. (Pubitemid 128717193)
88. Hayes JK, Stanley TH, Lind GH, East K, Smith B, Kessler K. A double-blind study to evaluate the safety of recombinant human hemoglobin in surgical patients during general anesthesia. J Cardiothorac Vasc Anesth 2001 15 : 593 602.
89. Li XZ, Yang QH, Yan JF, Xu K, Liu J, He XY, Zhang XW, Liu Q. Characterization of poly(ethylene glycol)-modified bovine hemoglobin by capillary zone electrophoresis. Artif Cells Blood Substit Biotechnol 2007 35 : 1 10.